BCR-ABL affects STAT5A and STAT5B differentially

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Schaller Schönitz, Michael ^a   Barzan, David ^a   Williamson, Andrew J K ^b   Griffiths, John R ^b   Dallmann, Iris ^a   Battmer, Karin ^a   Ganser, Arnold ^a   Whetton, Anthony D ^b   Scherr, Michaela ^a   Eder, Matthias ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; INTERLEUKIN 3; INTERLEUKIN 3 RECEPTOR; JANUS KINASE 2; PROTEIN BCL XL; STAT5A PROTEIN; STAT5B PROTEIN; BENZAMIDE DERIVATIVE; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; STAT5 PROTEIN; STAT5A PROTEIN, HUMAN; STAT5B PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DIMERIZATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; CELL LINE; FLUORESCENT ANTIBODY TECHNIQUE; GENE VECTOR; GENETICS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LENTIVIRINAE; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

BENZAMIDES; CELL LINE; CELL PROLIFERATION; DIMERIZATION; FLUORESCENT ANTIBODY TECHNIQUE; FUSION PROTEINS, BCR-ABL; GENETIC VECTORS; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; INTERLEUKIN-3; LENTIVIRUS; MASS SPECTROMETRY; PHOSPHORYLATION; PIPERAZINES; PYRIMIDINES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEINS;

EID: 84901290824     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097243     Document Type: Article

References (48)

1. Levy DE, Darnell JE Jr (2002) Stats: Transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651-662. (Pubitemid 34987786)
2. Mertens C, Darnell JE Jr (2007) SnapShot: JAK-STAT signaling. Cell 131: 612.
3. John S, Vinkemeier U, Soldaini E, Darnell JE Jr, Leonard WJ (1999) The significance of tetramerization in promoter recruitment by Stat5. Mol Cell Biol 19: 1910-1918. (Pubitemid 29098249)
4. Mui AL, Wakao H, O'Farrell AM, Harada N, Miyajima A (1995) Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs. EMBO J 14: 1166-1175.
5. Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, et al. (1997) Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 11: 179-186. (Pubitemid 27081895)
6. Park SH, Liu X, Hennighausen L, Davey HW, Waxman DJ (1999) Distinctive roles of STAT5a and STAT5b in sexual dimorphism of hepatic P450 gene expression. impact of STAT5a gene disruption. J Biol Chem 274: 7421-7430.
7. Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, et al. (1998) Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 93: 841-850. (Pubitemid 28257589)
8. Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, et al. (1997) Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A 94: 7239-7244. (Pubitemid 27345299)
9. Burchill MA, Yang J, Vogtenhuber C, Blazar BR, Farrar MA (2007) IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol 178: 280-290. (Pubitemid 46033611)
10. Hoelbl A, Kovacic B, Kerenyi MA, Simma O, Warsch W, et al. (2006) Clarifying the role of Stat5 in lymphoid development and abelson-induced transformation. Blood 107: 4898-4906. (Pubitemid 43882643)
11. Yao Z, Cui Y, Watford WT, Bream JH, Yamaoka K, et al. (2006) Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci U S A 103: 1000-1005. (Pubitemid 43212211)
12. Yao Z, Kanno Y, Kerenyi M, Stephens G, Durant L, et al. (2007) Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 109: 4368-4375. (Pubitemid 46743405)
13. Gouilleux F, Wakao H, Mundt M, Groner B (1994) Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. EMBO J 13: 4361-4369. (Pubitemid 24295208)
14. Dumon S, Santos SC, Debierre-Grockiego F, Gouilleux-Gruart V, Cocault L, et al. (1999) IL-3 dependent regulation of bcl-xL gene expression by STAT5 in a bone marrow derived cell line. Oncogene 18: 4191-4199. (Pubitemid 29377850)
15. Gesbert F, Griffin JD (2000) Bcr/Abl activates transcription of the bcl-X gene through STAT5. Blood 96: 2269-2276.
16. Socolovsky M, Fallon AE, Wang S, Brugnara C, Lodish HF (1999) Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: A direct role for Stat5 in bcl-X(L) induction. Cell 98: 181-191.
17. Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96: 3343-3356.
18. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, et al. (1999) The biology of chronic myeloid leukemia. N Engl J Med 341: 164-172. (Pubitemid 29325745)
19. Ren R (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5: 172-183.
20. Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, et al. (2010) Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med 2: 98-110.
21. Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL (1996) Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 13: 247-254. (Pubitemid 26334856)
22. Ye D, Wolff N, Li L, Zhang S, Ilaria RL Jr (2006) STAT5 signaling is required for the efficient induction and maintenance of CML in mice. Blood 107: 4917-4925. (Pubitemid 43882645)
23. Scherr M, Chaturvedi A, Battmer K, Dallmann I, Schultheis B, et al. (2006) Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood 107: 3279-3287.
24. Scherr M, Battmer K, Ganser A, Eder M (2003) Modulation of gene expression by lentiviral-mediated delivery of small interfering RNA. Cell Cycle 2: 251-257.
25. Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, et al. (2007) Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood 109: 4399-4405. (Pubitemid 46743409)
26. Scherr M, Venturini L, Eder M (2009) Knock-down of gene expression in hematopoietic cells. Methods Mol Biol 506: 207-219.
27. Klucher KM, Lopez DV, Daley GQ (1998) Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression. Blood 91: 3927-3934. (Pubitemid 28225762)
28. Furqan M, Mukhi N, Lee B, Liu D (2013) Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res 1: 5-7771-1-5.
29. Quelle FW, Sato N, Witthuhn BA, Inhorn RC, Eder M, et al. (1994) JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region. Mol Cell Biol 14: 4335-4341.
30. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB (2006) Janus kinase 2: A critical target in chronic myelogenous leukemia. Cancer Res 66: 6468-6472. (Pubitemid 44085597)
31. Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, et al. (2002) The src family kinase hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J 21: 5766-5774. (Pubitemid 35315274)
32. Hantschel O, Warsch W, Eckelhart E, Kaupe I, Grebien F, et al. (2012) BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol 8: 285-293.
33. Braunstein J, Brutsaert S, Olson R, Schindler C (2003) STATs dimerize in the absence of phosphorylation. J Biol Chem 278: 34133-34140. (Pubitemid 37553254)
34. Wenta N, Strauss H, Meyer S, Vinkemeier U (2008) Tyrosine phosphorylation regulates the partitioning of STAT1 between different dimer conformations. Proc Natl Acad Sci U S A 105: 9238-9243.
35. Zhong M, Henriksen MA, Takeuchi K, Schaefer O, Liu B, et al. (2005) Implications of an antiparallel dimeric structure of nonphosphorylated STAT1 for the activation-inactivation cycle. Proc Natl Acad Sci U S A 102: 3966-3971. (Pubitemid 40388539)
36. Chatain N, Ziegler P, Fahrenkamp D, Jost E, Moriggl R, et al. (2013) Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells. Oncogene 32: 3587-3597.
37. Warsch W, Grundschober E, Berger A, Gille L, Cerny-Reiterer S, et al. (2012) STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia. Oncotarget 3: 1669-1687.
38. Casetti L, Martin-Lanneree S, Najjar I, Plo I, Auge S, et al. (2013) Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells. Cancer Res 73: 2052-2058.
39. Kazansky AV, Kabotyanski EB, Wyszomierski SL, Mancini MA, Rosen JM (1999) Differential effects of prolactin and src/abl kinases on the nuclear translocation of STAT5B and STAT5A. J Biol Chem 274: 22484-22492.
40. Feng J, Witthuhn BA, Matsuda T, Kohlhuber F, Kerr IM, et al. (1997) Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol Cell Biol 17: 2497-2501. (Pubitemid 27175130)
41. Gauzzi MC, Velazquez L, McKendry R, Mogensen KE, Fellous M, et al. (1996) Interferon-alpha-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase. J Biol Chem 271: 20494-20500. (Pubitemid 26281822)
42. van der Geer P, Wiley S, Gish GD, Pawson T (1996) The shc adaptor protein is highly phosphorylated at conserved, twin tyrosine residues (Y239/240) that mediate protein-protein interactions. Curr Biol 6: 1435-1444. (Pubitemid 27012242)
43. Zeidan Q, Hart GW (2010) The intersections between O-GlcNAcylation and phosphorylation: Implications for multiple signaling pathways. J Cell Sci 123: 13-22.
44. Zhou YJ, Hanson EP, Chen YQ, Magnuson K, Chen M, et al. (1997) Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity. Proc Natl Acad Sci U S A 94: 13850-13855. (Pubitemid 28009673)
45. Harir N, Pecquet C, Kerenyi M, Sonneck K, Kovacic B, et al. (2007) Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood 109: 1678-1686. (Pubitemid 46239602)
46. Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, et al. (2011) High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 117: 3409-3420.
47. Furqan M, Akinleye A, Mukhi N, Mittal V, Chen Y, et al. (2013) STAT inhibitors for cancer therapy. J Hematol Oncol 6: 90-8722-6-90.
48. Scherr M, Battmer K, Blomer U, Schiedlmeier B, Ganser A, et al. (2002) Lentiviral gene transfer into peripheral blood-derived CD34+ NOD/SCID-repopulating cells. Blood 99: 709-712. (Pubitemid 34533114)